Actualités GraniteShares ETF Trust GraniteShares - NVDL | Actions NASDAQ

Outils de qualité professionnelle, pour des investisseurs individuels.

NovaDel Pharma to Begin Trading on American Stock Exchange Tomorrow

NovaDel Pharma to Begin Trading on American Stock Exchange Tomorrow FLEMINGTON, N.J., May 10 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc...

NovaDel Pharma at Rodman & Renshaw TechVest Global Conference May 12

NovaDel Pharma at Rodman & Renshaw TechVest Global Conference May 12 FLEMINGTON, N.J., MAY 3 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc...

NovaDel Pharma's Third Foreign Patent Issued

NovaDel Pharma's Third Foreign Patent Issued FLEMINGTON, N.J., April 22 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN BOARD: NVDL...

NovaDel CEO Interviews on Wall Street Reporter

NovaDel CEO Interviews on Wall Street Reporter First FDA Approval Filing to Occur Within Next Two Months; Five Tier One Drugs Entering Proof of...

NovaDel CEO to Be Interviewed Tomorrow by Wall St. Reporter

NovaDel CEO to Be Interviewed Tomorrow by Wall St. Reporter FEMINGTON, N.J., April 15 /PRNewswire-FirstCall/ -- Gary Shangold, MD...

NovaDel Announces Update on Experimental Lingual Spray Drug Will Be Presented at Anesthesia Meeting

NovaDel Announces Update on Experimental Lingual Spray Drug Will Be Presented at Anesthesia Meeting FLEMINGTON, N.J., April 14...

NovaDel Reports First Quarter 2004 Progress

NovaDel Reports First Quarter 2004 Progress FLEMINGTON, N.J., Apr. 7 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN BOARD: NVDL...

NovaDel Names Robert G. Savage, Former Worldwide Head of Johnson & Johnson's Pharmaceutical Group, to Board

NovaDel Names Robert G. Savage, Former Worldwide Head of Johnson & Johnson's Pharmaceutical Group, to Board FLEMINGTON, N.J., March 1...

NovaDel Raises $14 Million in Private Offering

NovaDel Raises $14 Million in Private Offering New Funding Will Accelerate Human Feasibility Studies of Four Top-Selling Drugs; First NDA Filing...

NovaDel's Nitroglycerin Lingual Spray Achieves Important Safety and Efficacy Milestones In Randomized, Double-Blind Study

NovaDel's Nitroglycerin Lingual Spray Achieves Important Safety and Efficacy Milestones In Randomized, Double-Blind Study FLEMINGTON, N.J., Oct...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

GraniteShares ETF Trust GraniteShares (NVDL)

Outils de qualité professionnelle, pour des investisseurs individuels.

NVDL Actualités

NovaDel Pharma to Begin Trading on American Stock Exchange Tomorrow

NovaDel Pharma at Rodman & Renshaw TechVest Global Conference May 12

NovaDel Pharma's Third Foreign Patent Issued

NovaDel CEO Interviews on Wall Street Reporter

NovaDel CEO to Be Interviewed Tomorrow by Wall St. Reporter

NovaDel Announces Update on Experimental Lingual Spray Drug Will Be Presented at Anesthesia Meeting

NovaDel Reports First Quarter 2004 Progress

NovaDel Names Robert G. Savage, Former Worldwide Head of Johnson & Johnson's Pharmaceutical Group, to Board

NovaDel Raises $14 Million in Private Offering

NovaDel's Nitroglycerin Lingual Spray Achieves Important Safety and Efficacy Milestones In Randomized, Double-Blind Study

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

GraniteShares ETF Trust GraniteShares (NVDL) Actualités

GraniteShares ETF Trust GraniteShares (NVDL)

Outils de qualité professionnelle, pour des investisseurs individuels.

NVDL Actualités

NovaDel Pharma to Begin Trading on American Stock Exchange Tomorrow

NovaDel Pharma at Rodman & Renshaw TechVest Global Conference May 12

NovaDel Pharma's Third Foreign Patent Issued

NovaDel CEO Interviews on Wall Street Reporter

NovaDel CEO to Be Interviewed Tomorrow by Wall St. Reporter

NovaDel Announces Update on Experimental Lingual Spray Drug Will Be Presented at Anesthesia Meeting

NovaDel Reports First Quarter 2004 Progress

NovaDel Names Robert G. Savage, Former Worldwide Head of Johnson & Johnson's Pharmaceutical Group, to Board

NovaDel Raises $14 Million in Private Offering

NovaDel's Nitroglycerin Lingual Spray Achieves Important Safety and Efficacy Milestones In Randomized, Double-Blind Study

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres